Skip to main content
Clinical Trials/NCT03372824
NCT03372824CompletedNot Applicable

Oral Glucose Tolerance Test (OGTT), HbA1c or Glycated Albumin - Can we Reduce the Need for OGTT in Pregnancy?

Helse Stavanger HF1 site in 1 country148 target enrollmentStarted: November 1, 2017Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
148
Locations
1
Primary Endpoint
Glycated albumin reference interval in pregnancy

Study Overview

Brief Summary

This is an observational study at the Obstetrical outpatient clinic at Stavanger University Hospital, Norway. The purpose of the study is to compare glycated albumin and glycated hemoglobin (HbA1c), both markers of "long-term blood sugar" with oral glucose tolerance test (OGTT). The OGTT is a screening test for gestational diabetes, a condition that increases risk of adverse pregnancy outcome for mother and child. The risks are reduced with good glycaemic control throughout pregnancy, therefore, it is important to screen for gestational diabetes.

Detailed Description

According to the new guideline by the Norwegian Directorate of Health published april 2017, screening for gestational diabetes is increased. All pregnant women with a slight risk, approximately 70 % of pregnant women i Norway, should have an OGTT performed in gestational week 24-28. Among those women, all primiparas above the age of 25 years old.

The investigators will include 150 primiparas above the age of 25 years old in the study. The women will be asked to participate in the study when they attend an ultrasound examination at the Obstetric outpatient clinic in gestational week 18-20. Prior to inclusion, participants need to sign written informed consent.

Included women will get an appointment for OGTT in gestational week 24-28 at the Clinical trial unit, Stavanger University hospital. The OGTT will be performed according to national guidelines. The participants will fill in a single questionaire with information on age, height, ethnicity, whether there is diabetes in close family, any other illnesses, smoking habits and other medications/supplements.

In addition, to blood sugar levels, markers of importance for glycaemic control, iron status and vitamin-D status will be analyzed.

Women diagnosed with gestational diabetes or overt diabetes mellitus, will be followed up according to national guidelines.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
25 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • primiparas >25 years old
  • singleton pregnancy
  • Exclusion criteria:
  • prior diagnosed with diabetes

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Glycated albumin reference interval in pregnancy

Time Frame: gestational week 24-28

Glycated albumin will be analyzed by a new method based on mass spectrometry. Glycated albumin will be analyzed in blood samples taken during the OGTT.

Secondary Outcomes

  • Induction of labour(At delivery)
  • Preeclampsia(From gestational week 20 until 1 week postpartum)
  • Birth weight(At delivery)
  • Oral glucose tolerance test in pregnancy(Gestational week 24-28)
  • HbA1c(Gestational week 24-28)
  • Iron status(Gestational week 24-28)
  • Glycaemic control(Gestational week 24-37)
  • APGAR(At delivery)
  • Admission to neonatal intensive care unit(At delivery)

Investigators

Sponsor Class
Other Gov
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials